Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer

Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates 'unprecedented' benefit

2014-09-29

(Press-News.org) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically been one of the most aggressive forms of the disease.

"In CLEOPATRA we evaluated whether dual HER2 blockade by combining the antibody pertuzumab with trastuzumab and chemotherapy would help people live longer (overall survival, OS) or live longer without their disease worsening (progression-free survival, PFS)," explains lead author Dr Sandra Swain from Washington Hospital Center, Washington, USA.

New results presented at ESMO 2014 in Madrid showed that people treated with the combination lived 15.7 months longer than those who received trastuzumab and chemotherapy alone, with a median overall survival of 56.5 vs. 40.8 months. "The survival improvement of nearly 16 months observed in CLEOPATRA is unprecedented among studies of metastatic breast cancer," said Swain.

The study authors had previously reported that the pertuzumab regimen significantly extended progression-free survival and overall survival. The new data reports the results of the final analysis of survival in CLEOPATRA after a median of 50 months follow-up of patients.

In the current analysis, overall survival was analysed using all randomised patients, with no adjustments for cross-over once the study treatments were unblinded. Patients who crossed over from the placebo arm to the pertuzumab arm were analysed as part of the placebo arm, Swain explains. "As such, this is a very conservative final analysis of survival."

The overall survival benefit observed with the pertuzumab regimen in CLEOPATRA was consistent across patient subgroups, the researchers say, and the previously observed benefit in progression-free survival was maintained after long-term follow-up. The long-term safety profile of the pertuzumab regimen also was unchanged from previous analyses and the long-term cardiac safety profile was maintained.

"This is the kind of survival improvement for which we have worked, and this data will be incredibly meaningful to patients and their families," Swain said.

Javier Cortes, Director of the Breast Cancer Program at Vall D'Hebron Institute of Oncology in Barcelona, Spain, another author on the study, said: "The median overall survival data presented by Sandra Swain at ESMO 2014 with pertuzumab and trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer is remarkable. This is one of the biggest steps toward making this disease a chronic condition in the near future."

"What is more surprising is that the improvement in median overall survival exceeds the improvement in progression-free survival; maybe because of the different mechanisms of action that monoclonal antibodies have," Cortes said.

"We should consider this combination as the standard of care for our patients," Cortes added. "I can see no reason to justify the use of trastuzumab without pertuzumab. The impressive overall survival data we have observed at ESMO 2014 will help us, as physicians, to continue working; it will help patients, to fight against their disease; and it will help society to understand that people will not die of cancer in the future."

Looking to the future, researchers need to study the mechanisms of resistance to this combination, to improve its therapeutic activity and to try to identify which patients will not need chemotherapy, Cortes concluded.

INFORMATION:

ELSE PRESS RELEASES FROM THIS DATE:

Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer

2014-09-29

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid. In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very poor outlook. Only about 20-30% have tumour shrinkage after conventional chemotherapy and survival ...

Many patients lack information about the use of targeted therapies, oncologists say

2014-09-29

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain. The results come from an online survey of 895 doctors from 12 countries in Europe, South America and Asia. All were practicing oncology specialists, with more than three years' experience, treating more than fifteen patients a month. While 82% of those surveyed believed that deciding on a course of treatment ...

Under-representation of women in oncology leadership positions

2014-09-29

A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress. "In Greece, and across Europe, women oncologists still find it hard to access leadership or academic positions," said Dr Helena Linardou, Associate Director of the 1st Department of Oncology at the Metropolitan Hospital, Athens, Greece, who presented the survey results at the congress. "Women are indeed increasingly choosing oncology specialties in Greece, however, most decision-making posts ...

Is expressive suppression effective in reducing negative emotion?

2014-09-29

A recent study based on a Chinese sample gives an answer to this question. The research shows that in Chinese culture, emotion- expressive suppression is not only able to dampen negative emotion effectively, but also dampen negative emotion faster than Cognitive reappraisal. This sheds much light on how to quickly regulate negative emotion in urgent situations, particularly when people from East-Asian cultures are concerned. This study has been published in SCIENCE CHINA： Life Sciences (IN CHINESE) , which is titled "The efficiency of negative emotion regulation: ...

Using the brain to forecast decisions

2014-09-29

You're waiting at a bus stop, expecting the bus to arrive any time. You watch the road. Nothing yet. A little later you start to pace. More time passes. "Maybe there is some problem", you think. Finally, you give up and raise your arm and hail a taxi. Just as you pull away, you glimpse the bus gliding up. Did you have a choice to wait a bit longer? Or was giving up too soon the inevitable and predictable result of a chain of neural events? In research published on 09/28/2014 in the journal Nature Neuroscience, scientists show that neural recordings can be used to forecast ...

Smart, eco-friendly new battery to solve problems

2014-09-29

Present-day lithium batteries are efficient but involve a range of resource and environmental problems. Using materials from alfalfa (lucerne seed) and pine resin and a clever recycling strategy, Uppsala researchers have now come up with a highly interesting alternative. Their study will be presented soon in the scientific journal ChemSusChem. 'We think our discovery can open several doors to more environment-friendly, energy-efficient solutions for the batteries of the future,' says Daniel Brandell, Associate Professor at the Department of Chemistry, Uppsala University, ...

Protein that causes frontotemporal dementia also implicated in Alzheimer's disease

2014-09-29

SAN FRANCISCO, CA—September 28, 2014—Researchers at the Gladstone Institutes have shown that low levels of the protein progranulin in the brain can increase the formation of amyloid-beta plaques (a hallmark of Alzheimer's disease), cause neuroinflammation, and worsen memory deficits in a mouse model of this condition. Conversely, by using a gene therapy approach to elevate progranulin levels, scientists were able to prevent these abnormalities and block cell death in this model. Progranulin deficiency is known to cause another neurodegenerative disorder, frontotemporal ...

Predicting landslides with light

2014-09-29

WASHINGTON, Sept. 29, 2014—Optical fiber sensors are used around the world to monitor the condition of difficult-to-access segments of infrastructure—such as the underbellies of bridges, the exterior walls of tunnels, the feet of dams, long pipelines and railways in remote rural areas. Now, a team of researchers in Italy are expanding the reach of optical fiber sensors "to the hills" by embedding them in shallow trenches within slopes to detect and monitor both large landslides and slow slope movements. The team will present their research at The Optical Society's (OSA) ...

Scientists identify the signature of aging in the brain

2014-09-29

How the brain ages is still largely an open question – in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. The scientists believe that this discovery may lead, in the future, to treatments that can slow or ...

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

2014-09-29

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at the Moffitt Cancer Centre, Tampa, Florida. Nivolumab is an antibody ...